Last week everything from co-processed excipients to Viagra-stuffed teddies were discussed at AAPS 2010. Now, with the show having finished, we present our personal take on the event.
Agilent Technologies has launched its 708-DS Dissolution Apparatus, a quality control instrument that can be set up for manual or automated applications to measure the release rate of an API over time.
The USP is building a database of counterfeit essential medicines to support international drug procurement organisations, such as WHO, and the timely sharing of information between national regulators.
The European Medicines Agency (EMA) says 12-month API plant joint inspection programme has fostered greater collaboration between international drug industry regulators and cut the number of duplicate visits.
API maker AMRI cited arbitration costs, efforts to address a US FDA warning letter and acquisitions as key factors in Q3 loss, but predicted that large-scale contract manufacturing business will drive final quarter gains.
In the 20 month period before the heparin crisis no Chinese producers were inspected by the FDA and efforts during and since have been hindered by legal and practical challenges.
Celanese has launched a new controlled-release EVA excipient and says developing enhanced formulations is key to a drugmaker’s competitive edge in today’s pharmaceutical market.
Overseas offices will help the FDA schedule inspections more quickly in times of crisis but, as yet, employees based abroad have visited relatively few facilities.
Biopharm are increasingly assessing the threat counterfeiting and diversion pose to emerging biotechs when planning an acquisition, according to a white paper.
B. Braun is recalling lots of its injectable anticoagulant, Heparin, manufactured in 2008, after finding a sample used to manufacture Heparin Sodium USP active pharmaceutical ingredients (APIs) was contaminated.
Aoxing Pharma and Johnson Matthey team up to research, develop, manufacture and market active pharmaceutical ingredients (APIs) for narcotics and neurological drugs in China.
Drug industry demand for chemical intermediates and development projects has rebounded significantly in the last 12 months according to UK group Endeavour Specialty Chemicals.
The WHO is today initiating a pilot prequalification programme for selected APIs used in drugs for HIV and related diseases, antimalarials and anti-tuberculosis medications.
Pharmatek Laboratories has once again expanded service offerings at its San Diego, California facility by adding two roller compactors to its solid oral dosage form manufacturing capabilities.
IMS Health predicts that global drug sales will increase 5 to 7 per cent next year, driven by development of innovative pharmaceuticals and growth of emerging markets.
SoluBest and Dr Reddy’s Laboratories are joining forces to develop a proprietary formulation of one of SoluBest’s pipeline compounds using its Solumer platform.
Guy Villax, board member of the EFCG, talks falsified APIs, EU efforts to tackle the issue, and the presence of gangsters in the pharma industry in an in-PharmaTechnologist video interview.
Novartis will use technology from Synthetics Genomics Vaccines to speed up the development of influenza vaccines for seasonal and pandemic flu outbreaks.
China leads the field in 'potential future' API suppliers, positioning it to become a dominant force as these companies develop, Thomson Reuters said at CPhI 2010.
Univar is now exclusively distributing Dow's Carbowax Sentry PEGs in Europe and the range is proving popular at CPhI 2010 with manufacturers facing restricted supply from other sources.
Cost-effective, large-scale production of oncology drug Taxol (paclitaxel) intermediates could eventually be achieved using engineered Escherichia coli.
GlaxoSmithKline (GSK) has entered into two unrelated development deals by signing license agreements for Delphi Genetics’ StabyExpress for its vaccine production operations and OncoMethylome Sciences’ DNA methylation specific PCR biomarkers for its cancer...
Reengineering erythropoietin (EPO) as an immunoglobulin G (IgG) fusion protein enables penetration of the blood-brain barrier (BBB) in mice, according to researchers.
Life Technologies has concluded license agreements, providing rights to its proprietary Chinese hamster ovary (CHO) cell lines for production of recombinant proteins used as therapeutic agents and vaccines.
SOCMA CEO predicts reintroduction of rejected permanent R&D tax credit plan and urges Congress to act “sooner rather than later” to support US manufacturers.
DSM Pharma Chemicals, a business unit of DSM Pharmaceutical Products, has announced the launch of InnoSyn route scouting services, meeting pharma needs to outsource process development R&D.
NanGenex is introducing GMP bench-top and pilot plant reactors to scale-up its process for the continuous production of nanostructured active ingredients.
Cell culture, LAIV vaccines and recombinant DNA technology should be supported by the US government as part of a long-term overhaul of pandemic response capabilities, according to PCAST.
